Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by José A. López Martín
Based on 2 articles published since 2008

Between 2008 and 2019, J. A. L. Martín wrote the following 2 articles about Melanoma.
+ Citations + Abstracts
1 Clinical Trial Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma. 2009

Eisen, Tim / Thomas, José / Miller, Wilson H / Gore, Martin / Wolter, Pascal / Kavan, Petr / Martín, José A López / Lardelli, Pilar. ·Department of Oncology R4, Addenbrooke's Hospital, Cambridge, UK. tim.eisen@medschl.cam.ac.uk ·Melanoma Res · Pubmed #19436178.

ABSTRACT: The objective of this study was to evaluate the antitumor activity and safety profile of 5 mg/m2 plitidepsin administered as a 3-h continuous intravenous infusion every 2 weeks to patients with advanced malignant melanoma who relapsed or progressed after one line of systemic therapy. Objective response rate (primary efficacy endpoint) was evaluated according to Response Evaluation Criteria In Solid Tumors and toxicity was assessed using National Cancer Institute -Common Toxicity Criteria Version 2.0. Of 39 enrolled patients (median age: 53 years), 37 patients were treated who received a total of 167 treatment cycles (median: 3 cycles per patient; range: 1-32). All patients had received prior systemic therapy with a median of one line per patient (range: 1-6 lines). Of the 35 evaluable patients, two dacarbazine-resistant patients (5.7%) with metastatic cutaneous melanoma achieved partial responses. Five other patients (14.3%) reported stable disease (median stable disease duration: 3.5 months; range: 2.2-15.8 months). Therefore, the rate of tumor growth control was 20.0%. With a median follow-up of 11.0 months, the median progression-free survival was 1.3 months and the median overall survival was 3.5 months. Six patients (16.2%) had the following treatment-related grade 3/4 adverse events: myalgia (n = 3), injection-site reaction (n = 2), hypersensitivity, hypotension, and fatigue (n = 1 each). One patient was withdrawn from the trial because of grade 4 hypersensitivity reaction and hypotension. No severe neutropenia was reported. Plitidepsin showed a minor degree of antitumor activity in patients with refractory advanced malignant melanoma. Further evaluation of plitidepsin in combination schedules may be warranted.

2 Article SEOM guidelines for the management of Malignant Melanoma 2015. 2015

Berrocal, A / Arance, A / Espinosa, E / Castaño, A G / Cao, M G / Larriba, J L G / Martín, J A L / Márquez, I / Soria, A / Algarra, S M. ·Servicio de Oncología Médica, Consorcio Hospital General Universitario de Valencia, Avda. Tres Cruces 2, 46014, Valencia, Spain. berrocal.alf@gmail.com. · Hospital Clinic I Provincial de Barcelona, Barcelona, Spain. · Hospital Universitario la Paz, Madrid, Spain. · Hospital Universitario Marqués de Valdecilla, Santander, Spain. · Hospital Universitario Quirón Dexeus, Barcelona, Spain. · Hospital Universitario Clínico San Carlos, Madrid, Spain. · Hospital Universitario 12 de Octubre, Madrid, Spain. · Hospital General Universitario Gregorio Marañón, Madrid, Spain. · Hospital Universitario Ramón y Cajal, Madrid, Spain. · Clínica Universitaria de Navarra, Pamplona, Spain. ·Clin Transl Oncol · Pubmed #26669314.

ABSTRACT: All melanoma patients must be confirmed histologically and resected according to Breslow. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon must be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 therapy. Up to 10 years follow up is recommended for melanoma patients with dermatologic examinations and physical exams.